Premium
Parenteral Antiarrhythmic Drug Therapy in Ventricular Tachycardia/Ventricular Fibrillation : Evolving Role of Class III Agents—Focus on Amiodarone
Author(s) -
SCHEINMAN MELVIN M.
Publication year - 1995
Publication title -
journal of cardiovascular electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.193
H-Index - 138
eISSN - 1540-8167
pISSN - 1045-3873
DOI - 10.1111/j.1540-8167.1995.tb00367.x
Subject(s) - amiodarone , medicine , refractory (planetary science) , ventricular tachycardia , bretylium , cardiology , ventricular fibrillation , antiarrhythmic agent , atrial fibrillation , drug , anesthesia , pharmacology , heart disease , adrenergic , physics , receptor , astrobiology
Intravenous Amiodarone. More effective intravenous antiarrhythmic agents are required for treatment of patients with refractory malignant ventricular arrhythmias. More recently, a great deal of interest has been focused on use of intravenous amiodarone for these patients. Uncontrolled early studies showed that intravenous amiodarone was effective in 42% to 81% of treated patients. Recent large cooperative trials have documented the efficacy of intravenous amiodarone in these patients and have shown an efficacy comparable to bretylium in patients with refractory sustained ventricular tachycardia or fibrillation.